BERLDRG
Beryl Drugs financials
- Market cap
- ₹11 Cr
Quarterly results
Q1 FY27: revenue up 56.7%, net profit up 1000.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 5 | 5 | 5 | 5 −9% | 4 −29% | 5 +5% | 8 +57% |
| EBITDA | 1 | 1 | 1 | 1 | 1 +30% | -0 −134% | 1 +168% | 1 +18% |
| Net profit | 0 | 0 | 0 | 0 | 0 +0% | -0 −440% | 1 +273% | 0 +1000% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance 0.0% 1Y
1Y: ₹24.12 on 9 Sept 2025 → ₹24.12. High ₹25.53 (9 Apr 2026), low ₹16.87 (2 Mar 2026).
Financials, as filed
Revenue fell 15.6% a year over 2 years, FY24 to FY26. Operating margin widened to 12.5%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹27 Cr | ₹23 Cr | ₹19 Cr |
| Operating profit | ₹3 Cr | ₹3 Cr | ₹2 Cr |
| Operating margin | 9.8% | 11.7% | 12.5% |
| Interest | ₹0 Cr | ₹1 Cr | ₹0 Cr |
| Depreciation | ₹1 Cr | ₹1 Cr | ₹1 Cr |
| Net profit | ₹1 Cr | ₹1 Cr | ₹0 Cr |
| Net margin | 2.8% | 2.6% | 2.2% |
| Cash from operations | ₹1 Cr | ₹3 Cr | ₹4 Cr |
| Free cash flow | ₹-1 Cr | ₹1 Cr | ₹-0 Cr |
| ROCE | 11.1% | 10.2% | 7.2% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr |
| Reserves | ₹3 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr | ₹4 Cr | ₹5 Cr |
| Borrowings | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹2 Cr |
| Other liabilities | ₹6 Cr | ₹5 Cr | ₹5 Cr | ₹3 Cr | ₹4 Cr | ₹3 Cr |
| Total liabilities | ₹19 Cr | ₹18 Cr | ₹18 Cr | ₹17 Cr | ₹17 Cr | ₹15 Cr |
| Fixed assets | ₹8 Cr | ₹6 Cr | ₹6 Cr | ₹6 Cr | ₹8 Cr | ₹7 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹11 Cr | ₹12 Cr | ₹11 Cr | ₹11 Cr | ₹9 Cr | ₹8 Cr |
| Total assets | ₹19 Cr | ₹18 Cr | ₹18 Cr | ₹17 Cr | ₹17 Cr | ₹15 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, promoters added +1.44 pp while the public trimmed −1.42 pp. The shareholder count shrank 1% to 7,309.
- Promoters
- 27.8%
- Public
- 72.2%
Since Jun 2025
- Promoters +1.44 pp
- Public −1.42 pp
How it drifted, 12 quarters
Over this window promoters went from 26.4% to 27.8% — +1.4 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 26.4%, Public 73.6%.Dec '23: Promoters 26.4%, Public 73.6%.Mar '24: Promoters 26.4%, Public 73.6%.Jun '24: Promoters 26.4%, Public 73.6%.Sep '24: Promoters 26.4%, Public 73.6%.Dec '24: Promoters 26.4%, Public 73.6%.Mar '25: Promoters 26.4%, Public 73.6%.Jun '25: Promoters 26.4%, Public 73.6%.Sep '25: Promoters 26.4%, Public 73.6%.Dec '25: Promoters 26.4%, Public 73.6%.Mar '26: Promoters 27.5%, Public 72.5%.Jun '26: Promoters 27.8%, Public 72.2%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Pradeep Kumar Jain +1.02 pp 3.52% held
- Sudhir Sethi +0.34 pp 10.08% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Beryl Drugs Ltd. above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Sanjay Sethi | 10.88% | unchanged |
| Sudhir Sethi | 10.08% | +0.34 pp |
| Sangita Sethi | 3.78% | unchanged |
| Pradeep Kumar Jain | 3.52% | +1.02 pp |
| Soniya Sethi | 3.07% | unchanged |
| Mayank Siyal | 2.07% | unchanged |
| Samir Narendra Gupta | 1.77% | −0.14 pp |
| Jinesh Joseph | 1.67% | unchanged |
| Punjabhai Keshavbhai Jadeja | 1.23% | unchanged |
| Ram Babu Vijay | 1.19% | unchanged |
| Simimon Kallupurackal Joby | 1.05% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Beryl Drugs Ltd.
Guides on how to read this kind of business and the numbers that matter.